Growth Metrics

Neogenomics (NEO) EBT Margin (2016 - 2025)

Neogenomics (NEO) has disclosed EBT Margin for 16 consecutive years, with 6.52% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 285.0% year-over-year to 6.52%, compared with a TTM value of 15.16% through Dec 2025, down 295.0%, and an annual FY2025 reading of 15.16%, down 295.0% over the prior year.
  • EBT Margin was 6.52% for Q4 2025 at Neogenomics, up from 14.05% in the prior quarter.
  • Across five years, EBT Margin topped out at 60.33% in Q2 2021 and bottomed at 45.37% in Q1 2022.
  • Average EBT Margin over 5 years is 15.83%, with a median of 17.92% recorded in 2023.
  • The sharpest move saw EBT Margin surged 8097bps in 2021, then plummeted -9314bps in 2022.
  • Year by year, EBT Margin stood at 35.16% in 2021, then soared by 48bps to 18.4% in 2022, then soared by 47bps to 9.83% in 2023, then grew by 5bps to 9.38% in 2024, then surged by 30bps to 6.52% in 2025.
  • Business Quant data shows EBT Margin for NEO at 6.52% in Q4 2025, 14.05% in Q3 2025, and 25.27% in Q2 2025.